Targeted therapies for hormone-refractory prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 1108-1112, 2010.
Artículo
en Chino
| WPRIM
| ID: wpr-266227
ABSTRACT
Prostate cancer is one of the most common type of cancer among men after middle age. Androgen withdrawal can delay its progression in the initial stage, but it finally becomes independent of androgens in almost all the cases. The combination of docetaxel with prednisone is currently a standard first-line treatment for patients with hormone-refractory prostate cancer (HRPC), but hitherto there is no established second-line therapy. In view of the molecular pathogenesis of HRPC, this article presents an overview on several promising drugs that target specific pathways, involving angiogenesis, cell signaling, apoptosis and proliferation, and immune modulation, either as single agents or in combination with cytotoxic chemotherapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Farmacología
/
Neoplasias de la Próstata
/
Resistencia a Antineoplásicos
/
Quimioterapia
/
Hormonas
Límite:
Humanos
/
Masculino
Idioma:
Chino
Revista:
National Journal of Andrology
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS